StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Analysts at StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Capital lowered shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Price Performance

Shares of CYCC stock opened at $0.42 on Thursday. Cyclacel Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $9.69. The business’s fifty day moving average price is $0.94 and its 200 day moving average price is $1.49. The firm has a market capitalization of $892,465.00, a PE ratio of -0.03 and a beta of 0.56.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same period in the previous year, the business earned ($6.60) earnings per share. Equities research analysts expect that Cyclacel Pharmaceuticals will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.